Advances on drug-coated balloons.

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials Science

Background:

• Intravascular interventions have advanced significantly for coronary and peripheral arterial disease.
• Restenosis remains a major challenge, often termed the 'Achilles' heel' of percutaneous interventions.
• Current solutions like drug-eluting stents have limitations, including stent thrombosis and in-stent restenosis.

Purpose of the Study:

• To review the rationale and evidence for paclitaxel-coated balloons in preventing restenosis.
• To evaluate the efficacy of paclitaxel-eluting balloons as a non-stent-based local drug delivery system.
• To discuss the future perspective of drug-coated balloons in treating peripheral arterial disease.

Main Methods:

• Review of preclinical and clinical studies on paclitaxel-eluting balloons.
• Analysis of data regarding short-term drug exposure effects on injured arteries.
• Evaluation of restenosis rates and late lumen loss post-angioplasty.

Main Results:

• Short-term exposure to paclitaxel from balloons can reduce late lumen loss and restenosis.
• Paclitaxel-coated balloons show feasibility for immediate drug release to inhibit restenosis.
• Available data, though limited, suggest positive outcomes in coronary and peripheral arteries.

Conclusions:

• Paclitaxel-coated balloons represent a feasible strategy for restenosis inhibition.
• This technology offers a promising alternative to traditional drug-eluting stents.
• Further clinical data are needed, but the perspective for peripheral arterial disease is positive.